High Quality Content by WIKIPEDIA articles! Anavex Life Sciences Corp. is a biopharmaceutical company engaged in the discovery and development of new drugs for the treatment of neurological diseases and cancer, utilizing its proprietary drug discovery SIGMACEPTOR™ platform. The Anavex portfolio comprises novel, wholly owned sigma receptor agonists and antagonists. The company’s lead drug candidate for Alzheimer’s disease (AD), ANAVEX 2-73, is in Phase 1 clinical trials, getting assessed for its safety, maximally tolerated dose, pharmacokinetics and pharmacodynamics. The company has also started scale-up manufacturing for ANAVEX 1-41, its second lead compound, targeting depression and AD. With sufficient quantities of ANAVEX 1-41 in hand, the company will be in a position to advance the program and begin preclinical studies on large animals in the near term. Данное издание представляет собой компиляцию сведений, находящихся в свободном доступе в среде Интернет в целом, и в...

В наличии:
	Sprinter - 780 руб.	Перейти		Лучшая цена
	Books.Ru - 873 руб.	Перейти
Под заказ:
	OZON.ru - 870 руб.	Перейти

Рейтинг книги: 4 из 5, 3 голос(-ов).